Trial Profile
A Non-Randomized, Open-Label Study to Investigate the Effects of Imatinib Mesylate on the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Paracetamol
- Indications Chronic myeloid leukaemia
- Focus Pharmacokinetics
- Sponsors Novartis
- 29 Sep 2009 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
- 05 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 May 2009 Actual patient number (12) added as reported by ClinicalTrials.gov.